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Key messages
 ► Seven studies have investigated whether 
copper intrauterine devices (Cu- IUDs) 
are associated with an increased risk of 
women acquiring HIV, including a high- 
quality randomised controlled trial.
 ► The collective evidence does not indicate 
an increased risk of HIV acquisition 
among users of Cu- IUDs.
ABSTRACT
Objectives To review systematically copper 
intrauterine device (Cu- IUD) use and HIV 
acquisition in women.
Methods We searched Pubmed, Embase 
and the Cochrane Library between database 
inception and 26 June 2019 for longitudinal 
studies comparing incident HIV infection 
among women using an unspecified IUD or 
Cu- IUD compared with non- hormonal or no 
contraceptive users, or hormonal contraceptive 
users. We extracted information from included 
studies, assessed study quality, and summarised 
study findings.
Results From 2494 publications identified, seven 
met our inclusion criteria. One randomised 
controlled trial (RCT), judged “informative 
with few limitations”, found no statistically 
significant differences in HIV risk between users 
of the Cu- IUD and either intramuscular depot 
medroxyprogesterone acetate (DMPA- IM) or 
levonorgestrel implant. One observational 
study, deemed “informative but with important 
limitations”, found no statistically significant 
difference in HIV incidence among IUD users 
compared with women who had tubal ligation or 
who were not using any contraception. Another 
“informative but with important limitations” 
observational study found no difference in HIV 
incidence between Cu- IUD users and DMPA or 
norethisterone enanthate injectable, or implant 
users. An RCT considered “unlikely to inform the 
primary question” also found no difference in 
HIV risk between Cu- IUD and progestogen- only 
injectable users. Findings from the other three 
“unlikely to inform the primary question” cohort 
studies were consistent with the more robust 
studies suggesting no increased risk of HIV 
acquisition among Cu- IUD users.
Conclusion The collective evidence, including 
that from a large high- quality RCT, does not 
indicate an increased risk of HIV acquisition 
among users of Cu- IUDs.
InTRoduCTIon
For nearly 30 years, inconsistent evidence 
from epidemiological observational 
research has been accumulating that 
hormonal contraceptives (particularly 
depot medroxyprogesterone acetate 
(DMPA)- containing injectables) may 
be associated with an increased risk of 
women acquiring HIV. In June 2019, the 
Evidence for Contraceptive Options and 
HIV Outcomes (ECHO) trial reported 
HIV incidence rates in users of three 
common contraceptives: the copper intra-
uterine device (Cu- IUD), intramuscular 
DMPA (DMPA- IM) and the levonorge-
strel (LNG) implant.1 The ECHO trial 
sought to address, through randomisa-
tion, a key concern with previous obser-
vational studies; namely that of possible 
confounding (the distortion of the true 
relationship between contraceptive use and 
HIV acquisition because of a third factor 
linked to both exposure and outcome), 
especially in relation to condom use and 
other sexual behaviours. Cu- IUD users 
have often been used as a reference group 
in the observational studies of hormonal 
contraceptives and HIV risk because of an 
assumption that Cu- IUDs do not increase 
the risk. This assumption is supported by 
a small biological study of genital tract 
immune cell changes after insertion of a 
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Cu- IUD which did not indicate increased susceptibility 
to HIV infection.2 Other biological studies have found 
that copper as a solution3 or filter4 deactivates HIV. It 
is important to know if Cu- IUDs affect, positively or 
negatively, the risk of HIV acquisition among users. 
We report here a systematic review of longitudinal 
epidemiological studies which have examined the risk 
of HIV acquisition among users of the Cu- IUD.
MeThodS
This systematic review adhered to the Preferred 
Reporting Items for Systematic Reviews and Meta- 
Analysis (PRISMA) guidelines.5 We examined two 
related but slightly different review questions as 
follows. (1) Among women at risk of HIV (ie, women 
who are HIV- seronegative at baseline), does use of a 
Cu- IUD compared with use of another non- hormonal 
contraceptive method or no contraceptive method 
increase the risk of HIV acquisition? (2) Among women 
at risk of HIV (ie, women who are HIV- seronegative at 
baseline), does use of a Cu- IUD compared with use of 
a specific hormonal contraceptive method increase the 
risk of HIV acquisition?
Inclusion and exclusion criteria
We included studies of women of reproductive age 
at risk of HIV infection (ie, seronegative for HIV 
at baseline) that compared incident, laboratory- 
confirmed HIV infection among women using a 
Cu- IUD compared with women using a non- hormonal 
method (eg, condom, sterilisation, fertility awareness- 
based methods, withdrawal) or no contraception. We 
also included studies comparing incident HIV infec-
tions among users of Cu- IUDs with another specified 
hormonal contraceptive (eg, DMPA or other inject-
able, oral contraceptive (OC), ring, patch or implant) 
users. We included longitudinal studies (observational 
studies, randomised controlled trials (RCTs) or meta- 
analyses); cross- sectional studies, letters, narrative 
reviews, conference abstracts and other non- primary 
research reports were excluded. We contacted the chief 
investigators of studies that did not specify the type of 
IUD (ie, device was simply referred to throughout as 
‘IUD’) used by participants to ascertain whether the 
usage related to Cu- IUDs rather than LNG- IUDs or 
inert IUDs (ie, IUDs with no bioactive component)
Search strategy
We searched Pubmed, Embase and the Cochrane 
Library from database inception to 26 June 2019 
(online supplementary appendix 1). We hand- searched 
reference lists of included studies. All authors screened 
abstracts and full- text articles using Covidence,6 
and conflicts were resolved through discussion. Two 
authors (KC and AT) also screened all the articles 
included in a companion review of hormonal contra-
ceptive use and risk of HIV acquisition7 to identify any 
additional studies that included an IUD- only arm.
data extraction, quality assessment and data synthesis
We used a study quality assessment framework modi-
fied from that used for a previous review of hormonal 
contraceptive use and risk of HIV.8 Briefly, studies 
that failed to adjust for condom use or had unclear 
exposure measurement were judged to be “unlikely 
to inform the primary question”. All other studies 
could be considered to be either “informative but 
with important limitations” or “informative with few 
limitations”, depending on the potential for residual 
or uncontrolled confounding in the studies (online 
supplementary appendix 2). We abstracted data 
from all included studies into an evidence table that 
included information on the study design, population, 
exposure and comparison groups, results, strengths 
and weaknesses, and quality. We synthesised the study 
results narratively; the small number of point estimates 
for specific comparisons precluded meta- analysis. For 
studies that reported risk estimates for a hormonal 
contraceptive method compared with a Cu- IUD, we 
report the inverse of the risk estimate so that the 
Cu- IUD is the exposure and the hormonal contracep-
tive method is the referent group.
Patient and public involvement
As this analysis was based on published data, patients and 
the public were not involved in the design of the study.
ReSulTS
description of included studies
We screened 2494 abstracts and 29 full- text reports 
(figure 1). We excluded 23 full- text reports – one 
reported data subsequently updated in a later report, 
10 were letters or conference abstracts, and 12 had an 
irrelevant exposure, outcome, study design or partici-
pant group. An ‘in press’ full report of a new study that 
has now been published9 was identified from a confer-
ence abstract.10 Seven studies met our inclusion criteria 
(table 1):1 9 11–15 five cohort studies9 11–14 and two 
RCTs.1 15 The studies were conducted in six countries: 
Eswatini, Italy, Kenya (three studies), Tanzania, South 
Africa (three studies) and Zambia. Between 343 and 
7830 women were enrolled into the different studies, 
conducted in a variety of clinical settings: hospital or 
outpatient clinics serving HIV- infected people, family 
planning clinics, a clinic for sex workers, hospital- 
based pregnancy termination services or clinical trial 
sites for a novel vaginal ring containing dapivirine. 
Three studies did not specify the type of IUDs that were 
used.11 12 14 Two of these studies were conducted in 
Kenya and the study authors confirmed that Cu- IUDs 
were the type of IUD available during the study.12 14 
The third study included two IUD users in Italy;11 the 
study authors were unable to provide information on 
the type of IUD used. One study was deemed to be 
“informative with few limitations”,1 two “informative 
but with important limitations”,9 14 and four “unlikely 
to inform the primary question”.11–13 15
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Figure 1 Identification of included studies.
Four studies11–14 addressed our first review ques-
tion, namely among women at risk of HIV (ie, women 
who are HIV- seronegative at baseline), does use of a 
Cu- IUD compared with use of another non- hormonal 
contraceptive method or no contraceptive method 
increase the risk of HIV acquisition? The only study 
classified as “informative but with important limita-
tions” reported on 10- year follow- up of 1498 sero-
negative women recruited from a clinic for female 
sex workers in Mombasa, Kenya conducted between 
1993 and 2003.14 A total of 15 428 follow- up visits 
accumulated; median number 6 (interquartile range, 
IQR 2–15), median interval between visits 35 (IQR 
28–55) days. Thirty- one women in the study used an 
IUD. Overall, 248 women seroconverted, although 
the number in each contraceptive group was not 
reported. Multivariate Cox proportional hazards 
models compared time- varying exposure to an IUD 
with no contraception or tubal ligation, with adjust-
ments including number of sexual partners each week, 
condom use, vaginal douching with soap products, 
and presence of a sexually transmitted infection or 
other genital infection before acquisition of HIV. The 
adjusted hazards ratio (adjHR) for IUD use compared 
with no contraception or tubal ligation was 1.1 (95% 
confidence interval, CI 0.4 to 3.0).
The second study followed 343 women living in Italy 
with an HIV- infected male partner.11 This longitudinal 
study conducted between 1987 and 1991 followed 
women enrolled in an earlier cross- sectional study 
that had advised women with an IUD to discontinue 
use because the baseline data suggested a three- fold 
increased risk of HIV prevalence among IUD users.16 
Despite this counselling, two women continued to use 
an IUD; the rest of the women did not use IUDs. One 
of the IUD users, who did not use condoms, serocon-
verted during longitudinal observation.11 The very 
small number of exposed women, and long interval (at 
least 6 months) between study visits, contributed to an 
assessment that the study was “unlikely to inform the 
primary question”.
In the third longitudinal study, 1537 seronegative 
women attending a family planning clinic in Nairobi, 
Kenya were followed every 3 months between 1990 
and 1992 as a pilot to test the feasibility of a larger study 
of contraception and HIV acquisition in women.12 
Sixteen women in the entire cohort, seven of whom 
were IUD users, seroconverted within 12 months of 
study entry. The cumulative life table HIV incidence 
rate at 12 months per 100 IUD users at admission was 
1.66 per 100 (95% CI 0.4 to 2.9) compared with 1.92 
per 100 (95% CI 0.0 to 4.6) among DMPA users and 
4.45 per 100 (95% CI 0.5 to 8.4) in OC users. This 
study was deemed “unlikely to inform the primary 
question”, partly because of the failure to report time- 
varying analyses of contraceptive exposure or relative 
risk estimates.
Another cohort study of women attending three 
family planning clinics in Dar es Salaam, Tanzania 
followed 1370 seronegative service users between 
1992 and 1995.13 Few women were using a Cu- IUD 
at baseline (4.1%), compared with OCs (63.4%), 
DMPA (4.2%), other methods (8.0%) and no methods 
(20.3%). Study follow- up visits coincided with routine 
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family planning visits, with the length of interval 
between visits undefined. Limited resources meant 
that blood for HIV testing could not be collected at 
every follow- up visit. Eight of the 75 women who sero-
converted had ever used a Cu- IUD during follow- up, 
giving an adjusted relative risk (adjRR) of 0.80 (95% 
CI 0.38 to 1.69) compared with never- users of a 
Cu- IUD. There was no relationship with duration 
of Cu- IUD use. The adjustments included number 
of sexual partners but not condom use, although the 
authors reported that inclusion of ever- use of condom 
in the model did not materially change the results. The 
ill- defined follow- up interval, limited HIV testing, and 
failure to use time- varying exposure information for 
the risk estimates meant that this study was judged to 
be “unlikely to inform the primary question”.
Three studies1 9 15 addressed our second review 
question, namely among women at risk of HIV (ie, 
women who are HIV- seronegative at baseline), does 
use of a Cu- IUD compared with use of a specific 
hormonal contraceptive method increase the risk of 
HIV acquisition? One study was judged to be “infor-
mative with few limitations”.1 The ECHO trial was an 
RCT specifically designed to compare HIV incidence 
among women using Cu- IUDs, DMPA- IM or LNG 
implants; a comparison group of women not using any 
contraception was not included. It was conducted in 
12 sites in Eswatini, Kenya, South Africa and Zambia, 
recruiting HIV- seronegative women aged 16–35 years 
and seeking contraception, with follow- up for up to 
18 months. After randomisation to one of the three 
contraceptive methods, study visits occurred every 3 
months and included HIV testing, contraceptive coun-
selling, behavioural assessment, and HIV prevention 
services. Outcome assessment for HIV was conducted 
without knowledge of the contraception assignment, 
and the study worked to ensure that information and 
counselling provided did not differ between the study 
groups. Ninety- nine percent of women accepted their 
assigned method. Participants used their assigned 
method for most (92%) of the 10 409 woman- years 
of follow- up. More than 91% of participants attended 
each scheduled follow- up visit and 99% had at least 
one follow- up HIV test. The overall incidence of HIV 
was 3.81 per 100 woman- years, with no statistically 
significant differences observed in rates between the 
three contraceptive groups. The main modified inten-
tion- to–treat analysis found a HR 0.96 (96% CI 0.75 
to 1.22) for the Cu- IUD compared to DMPA- IM (note 
that this estimate is the inverse of that reported by 
the authors) and HR 1.18 (96% CI 0.91 to 1.53) for 
Cu- IUD compared with the LNG implant. A prespeci-
fied sensitivity analysis of participants with continuous 
use of the contraceptive method assigned, adjusting for 
baseline and time- varying covariates including condom 
use, yielded similar results. Strengths of the ECHO 
trial included robust randomisation and allocation 
procedures, high rates of follow- up and continuation 
with assigned contraceptive methods, assessment 
of condom use and sexual behaviour as possible 
confounders, and appropriate intention- to- treat and 
prespecified sensitivity analyses. Although women and 
providers of services in the ECHO trial could not be 
blinded to contraceptive group allocation, HIV testing 
was conducted without knowledge of allocation, and 
there was no evidence that this led to the different 
groups of women acting, or being managed, differently 
with respect to important issues such as HIV preven-
tion counselling.
A cohort study, judged to be “informative but 
with important limitations”, included 1136 HIV- 
seronegative women from South African sites origi-
nally recruited for a double- blind, placebo- controlled 
RCT of a monthly vaginal ring containing dapivirine 
for HIV-1 prevention.9 Trial participants attended 
monthly visits between 2012 and 2015, where stan-
dardised information about sexual behaviour and 
contraceptive use was collected, and pregnancy 
and HIV infection status were tested. Cu- IUD use 
comprised 15.1% of the 1771 women- years of 
follow- up included in the analysis, with DMPA use 
50.7%, norethisterone enanthate (NET- EN) use 
25.4% and implant use 8.8%. A total of 95 women 
seroconverted. The adjusted Cox proportional 
hazards model included time- varying condom use 
and number of sexual partners. The Cu- IUD was not 
associated with a significantly altered risk of HIV 
acquisition when compared with any of the hormonal 
contraceptive methods (note that these estimates are 
the inverse of those reported by the authors): adjHR 
compared with DMPA 1.10 (95% CI 0.53 to 2.27); 
NET- EN 0.98 (95 % CI 0.47 to 2.04); implant 2.17 
(95% CI 0.59 to 7.69); all three hormonal methods 
together 1.11 (95% CI 0.57 to 2.22).
The third study was a pragmatic, open- label, paral-
lel- arm RCT conducted at termination of pregnancy 
services within two hospitals in South Africa between 
2009 and 2012.15 Participants were randomised to 
receive an injectable progestogen- only contraceptive 
(mostly DMPA, but sometimes NET- EN at the provid-
er’s discretion) or a Cu- IUD, and were followed up 
every 3 months. Forty- two women seroconverted, 22 
of those allocated to use a Cu- IUD. The intention- 
to- treat analysis included 656 injectable users and 
634 Cu- IUD users with a follow- up HIV test. The 
intention- to- treat unadjusted RR between injectable 
and Cu- IUD users was 0.88 (95% CI 0.48 to 1.59); 
per- protocol unadjusted RR 0.94 (95% CI 0.52 to 
1.71). Separate per- protocol unadjusted risk esti-
mates for the two injectables were: DMPA 1.01 (95% 
CI 0.55 to 1.86) and NET- EN 0.58 (95% CI 0.14 to 
2.42); each compared with Cu- IUD users. The trial 
was considered “unlikely to inform the primary ques-
tion” as it did not report on switching between groups 
after study entry or discontinuation rates, nor did it 
provide adjusted risk estimates.
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Figure 2 Intrauterine device use and risk of HIV acquisition in “informative with few limitations” or “informative but with important limitations” studies. 
*Estimates are the inverse associations of those reported by the authors. adjHR, adjusted hazard ratio; CI, confidence interval; Cu- IUD, copper intrauterine 
device; DMPA, depot medroxyprogesterone acetate; HR, hazard ratio; ITT, intention- to- treat; LNG, levonorgestrel; NET- EN, norethisterone enanthate
Iud use versus non-hormonal contraceptive use in studies 
considered “informative but with important limitations” 
or “informative with few limitations”
The only “informative but with important limita-
tions” study able to examine whether IUDs are asso-
ciated with an increased risk of HIV when compared 
with non- hormonal or no contraception did not find 
such an effect (figure 2).14 No studies were consid-
ered “informative with few limitations” for this 
question.
Iud use versus a specified hormonal contraceptive use 
in studies considered “informative but with important 
limitations” or “informative with few limitations”
One “informative with few limitations” study 
provided high- quality evidence that Cu- IUD users 
had a similar risk of acquiring HIV to that seen in 
users of DMPA- IM or the LNG implant (figure 2).1 
This evidence was consistent with another “informa-
tive but with important limitations” study that found 
no evidence of differences in HIV risk between IUD 
users and users of three hormonal contraceptives, 
regardless of whether each hormonal method was 
examined separately or together.9
dISCuSSIon
This systematic search of the literature from biblio-
graphic database inception to 26 June 2019 identified 
five cohort studies and two RCTs that met our inclu-
sion criteria; one was deemed sufficiently robust to 
meet our “informative with few limitations” criteria,1 
and two were deemed “informative but with impor-
tant limitations”.9 14 None of these studies indicated 
an increased risk of HIV acquisition among IUD users, 
irrespective of whether the comparison group included 
non- hormonal or no contraceptive users, or users of a 
specific hormonal contraceptive method. None of the 
lower- quality “unlikely to inform the primary ques-
tion” studies11–13 15 provided evidence inconsistent 
with the more robust studies.
Our search identified a large number of potential 
papers and we cross- checked the reference lists of 
included studies. It is unlikely, therefore, that we 
missed additional published data that could inform 
our research questions. We excluded cross- sectional 
studies since it is impossible to determine in such 
studies the time relationship between contracep-
tive use and HIV infection acquisition. While some 
studies did not specify IUD type, given the coun-
tries and years studied, the IUDs were most likely 
copper- bearing.
The ECHO trial was not designed to determine 
whether Cu- IUD use increases the risk of HIV 
acquisition compared with using no contraception.1 
Instead, it provided direct, high- quality evidence 
of an absence of increased risk of acquiring HIV 
among Cu- IUD users, compared with women using 
DMPA- IM injectables or LNG implants. There 
was no evidence that the different contraceptive 
groups in the ECHO trial acted, or were managed, 
differently with respect to key issues such as HIV 
prevention counselling. Furthermore, secondary 
sensitivity analyses controlled for important time- 
varying confounders such as condomless sex. It 
is highly unlikely, therefore, that the ECHO trial 
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results were affected by residual confounding (a key 
concern when interpreting observational studies). 
The high incidence of HIV in the ECHO trial, and 
low losses to follow- up, meant that it had sufficient 
statistical power to detect a 30% increase in risk of 
HIV between contraceptive groups assessed. Thus, it 
addressed another important limitation of previous 
observational studies, namely low power because 
of limited IUD usage or small number of women 
seroconverting.
Information from an early draft of this review, 
which considered only observational studies and RCTs 
published before the ECHO trial, was presented at a 
2019 WHO Guideline Development Group meeting to 
assess recommendations on contraception for women at 
high risk of HIV. 17
ConCluSIon
The collective evidence from this review, which now 
includes information from a large high- quality RCT, 
does not indicate evidence of an increased risk of HIV 
acquisition among users of Cu- IUDs.
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